|
|
| Zeile 9: |
Zeile 9: |
| | | colspan=2 bgcolor="#F6F3EE"|''substanceAdminSubstitution'' | | | colspan=2 bgcolor="#F6F3EE"|''substanceAdminSubstitution'' |
| | | bgcolor="#F6F3EE"|2.16.840.1.113883.5.1070 | | | bgcolor="#F6F3EE"|2.16.840.1.113883.5.1070 |
| − | | bgcolor="#F6F3EE"|2012-07-24 | + | | bgcolor="#F6F3EE"|2012-07-24T00:00:00 |
| | | bgcolor="#F6F3EE"|definitiv | | | bgcolor="#F6F3EE"|definitiv |
| | |- | | |- |
| Zeile 17: |
Zeile 17: |
| | | bgcolor="#ECE9E4" colspan="2"|'''Beschreibung''' | | | bgcolor="#ECE9E4" colspan="2"|'''Beschreibung''' |
| | |- | | |- |
| − | |-
| |
| − | |0-A
| |
| − | |_ActSubstanceAdminSubstitutionCode
| |
| − | |<font color="grey">(en-US)</font> ActSubstanceAdminSubstitutionCode
| |
| − | | colspan="2" |<p>Description: Substitution occurred or is permitted with another product that may potentially have different ingredients, but having the same biological and therapeutic effects.</p>
| |
| − | |-
| |
| − | |1-S
| |
| − | |'''E'''
| |
| − | |<font color="grey">(en-US)</font> equivalent
| |
| − | | colspan="2" |<p>Description: Substitution occurred or is permitted with another bioequivalent and therapeutically equivalent product.</p>
| |
| − | |-
| |
| − | |2-S
| |
| − | |'''EC'''
| |
| − | |<font color="grey">(en-US)</font> equivalent composition
| |
| − | | colspan="2" |<p>Description: Substitution occurred or is permitted with another product that is a: pharmaceutical alternative containing the same active ingredient but is formulated with different salt, ester pharmaceutical equivalent that has the same active ingredient, strength, dosage form and route of administration Examples: Pharmaceutical alternative: Erythromycin Ethylsuccinate for Erythromycin Stearate Pharmaceutical equivalent: Lisonpril for Zestril</p>
| |
| − | |-
| |
| − | |3-L
| |
| − | |'''BC'''
| |
| − | |<font color="grey">(en-US)</font> brand composition
| |
| − | | colspan="2" |<p>Description: Substitution occurred or is permitted between equivalent Brands but not Generics Examples: Zestril for Prinivil Coumadin for Jantoven</p>
| |
| − | |-
| |
| − | |3-L
| |
| − | |'''G'''
| |
| − | |<font color="grey">(en-US)</font> generic composition
| |
| − | | colspan="2" |<p>Description: Substitution occurred or is permitted between equivalent Generics but not Brands Examples: Lisnopril (Lupin Corp) for Lisnopril (Wockhardt Corp)</p>
| |
| − | |-
| |
| − | |2-S
| |
| − | |'''TE'''
| |
| − | |<font color="grey">(en-US)</font> therapeutic alternative
| |
| − | | colspan="2" |<p>Description: Substitution occurred or is permitted with another product having the same therapeutic objective and safety profile. Examples: ranitidine for Tagamet</p>
| |
| − | |-
| |
| − | |3-L
| |
| − | |'''TB'''
| |
| − | |<font color="grey">(en-US)</font> therapeutic brand
| |
| − | | colspan="2" |<p>Description: Substitution occurred or is permitted between therapeutically equivalent Brands but not Generics> Examples: Zantac for Tagamet</p>
| |
| − | |-
| |
| − | |3-L
| |
| − | |'''TG'''
| |
| − | |<font color="grey">(en-US)</font> therapeutic generic
| |
| − | | colspan="2" |<p>Description: Substitution occurred or is permitted between therapeutically equivalent Generics but not Brands> Examples: Ranitidine for cimetidine</p>
| |
| − | |-
| |
| − | |1-L
| |
| − | |'''F'''
| |
| − | |<font color="grey">(en-US)</font> formulary
| |
| − | | colspan="2" |<p>Description: This substitution was performed or is permitted based on formulary guidelines.</p>
| |
| − | |-
| |
| − | |1-L
| |
| − | |'''N'''
| |
| − | |<font color="grey">(en-US)</font> none
| |
| − | | colspan="2" |<p>No substitution occurred or is permitted.</p>
| |
| | |} | | |} |
